Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial.

Seher SenerEldad Ben-CheritIvan FoeldvariGil AmarilyoHuri OzdoganSteven VanderschuerenKatherine MarzanJ Michelle KahlenbergElise DekkerFabrizio De BenedettiIsabelle Kone-Paut

Published in: Annals of the rheumatic diseases (2020)

crFMF patients treated with canakinumab during 72 weeks experienced a minimal incidence of flares and good control of clinical disease activity, with no new safety concerns reported.

Keyphrases

phase iii
disease activity
open label
clinical trial
rheumatoid arthritis
double blind
systemic lupus erythematosus
placebo controlled
rheumatoid arthritis patients
phase ii
ankylosing spondylitis
juvenile idiopathic arthritis
study protocol
risk factors
early onset